These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34170537)

  • 1. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testing.
    Emrich T; Schattenberg JM
    Aliment Pharmacol Ther; 2021 Jul; 54(2):214-215. PubMed ID: 34170537
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors' reply.
    Park JG; Jung J; Loomba R
    Aliment Pharmacol Ther; 2021 Jul; 54(2):216. PubMed ID: 34170539
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient.
    De Vincentis A; Antonelli-Incalzi R; Picardi A; Vespasiani-Gentilucci U
    J Diabetes Complications; 2021 May; 35(5):107891. PubMed ID: 33642147
    [No Abstract]   [Full Text] [Related]  

  • 4. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
    Song DS; Chang UI; Kang SG; Song SW; Yang JM
    Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease.
    Basheer M; Naffaa M; Assy N
    Clin Mol Hepatol; 2023 Apr; 29(2):398-400. PubMed ID: 36775835
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    Li W
    J Hepatol; 2020 Aug; 73(2):465-466. PubMed ID: 32416974
    [No Abstract]   [Full Text] [Related]  

  • 9. The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    Liu M; Sun L; Mao Y
    J Hepatol; 2021 Apr; 74(4):970-971. PubMed ID: 33340576
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    Ampuero J; Gallego-Durán R; Romero-Gómez M
    J Hepatol; 2021 Apr; 74(4):971-972. PubMed ID: 33359898
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of fatty liver by computed tomography coronary artery calcium score.
    Kerut SE; Balart JT; Kerut EK; McMullan MR
    Echocardiography; 2017 Jun; 34(6):937-938. PubMed ID: 28493399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease is associated with subclinical coronary artery disease in otherwise healthy individuals.
    Wong MYZ; Yap JJL; Cheah MCC; Goh GBB; Yeo KK
    Ann Acad Med Singap; 2021 Jun; 50(6):500-502. PubMed ID: 34195761
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.
    Yang NB; Li GX; Chu JG; Wang YJ
    Hepatology; 2020 Jun; 71(6):2172-2173. PubMed ID: 31849080
    [No Abstract]   [Full Text] [Related]  

  • 15. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.